Pharvaris reports Q2 2026 results, expects CHAPTER-3 data in third quarter
The company said cash reached €318 million as it awaits pivotal HAE data and an April 2027 FDA decision on deucrictibant IR.
Pharvaris N.V. reported second quarter 2026 financial results and a business update on August 12, 2026. Cash and cash equivalents were €318 million as of June 30, 2026, compared to €292 million for December 31, 2025.1
The company's main late-stage readout is approaching. CHAPTER-3 is a placebo-controlled Phase 3 trial testing an extended-release tablet form of deucrictibant, taken orally, to prevent angioedema attacks in patients with HAE who are 12 years or older.1 The study enrolled 85 participants, randomized 2:1 to receive the 40 mg/day XR dose intended for commercial use, or placebo, dosed once daily over 24 weeks.1 Pharvaris expects to announce topline data from CHAPTER-3 in the third quarter of 2026.1
On the regulatory side, the FDA accepted the company's New Drug Application for deucrictibant IR for on-demand treatment of HAE attacks in July 2026, setting a PDUFA action date of April 23, 2027.1 The EMA also validated the corresponding marketing authorization application in July 2026 and began its formal review under the centralized procedure.1
Separately, CREAATE is a pivotal Phase 3 trial testing oral deucrictibant for both preventing and treating attacks in patients with acquired angioedema due to C1 inhibitor deficiency, and is being run at sites worldwide.1
On finances, R&D expenses were €35.0 million for the quarter, up from €29.6 million a year earlier,1 and the quarterly loss was €47.8 million, or €0.70 per share, compared with a €45.5 million loss, or €0.83 per share, in the same quarter of 2025.1 The company also closed a $132 million underwritten stock offering, with proceeds of $132.3 million extending its cash runway into 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.